This literature case reported by health care professionals, concerns Caucasian patients of unknown age (mean 
age: 57.5) and of unknown gender. The patients medical history included advanced non-small cell lung cancer 
(NSCLC) with non-squamous histology who had failed first-line platinum-based chemotherapy. Concomitant 
medication included zibotentan for unknown indication. The patient received pemetrexed (unknown manufacturer), 
500 mg/m2, via an unknown route, three-weekly, for the treatment of advanced non-small cell lung cancer 
(NSCLC). It was reported that the patients were evaluated every week for the first three weeks of the study and 
then on a three weekly basis. On an unknown date, time to onset unknown, the patient died due to dyspnoea. The 
event was also considered serious for other medically significant reasons. There were no patient laboratory results 
and corrective treatment reported. It was unknown if an autopsy was performed. 'It was unknown if the patient was 
receiving pemetrexed till time of death. The reporting health care professionals stated that the event was related 
to pemetrexed. The case is linked with FR201105000581, FR201105000606, FR201105000607 and 
FR201105000617. Literature Citation: Chouaid C. Nathan F. Pemberton K. Morris T.. A phase II, randomized, 
multicenter study to assess the efficacy, safety, and tolerability of zibotentan (ZD4054) in combination with 
Print Time: 02-SEP-2014 01:09 PM If a field is blank, there is no data for that field Page 43 of 831 
FDA - Adverse Event Reporting System (FAERS) 
FOIA Case Report Information 
pemetrexed in patients with advanced non-small cell lung cancer. Cancer Chemotherapy & Pharmacology. 
67(5):1203-8, 2011 May. 2011; 67(5) 1203-8.